We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
白介素17 与结直肠癌.
- Authors
茅慧; 千年松; 周艳华; 施伟伟; 郭亚军
- Abstract
Colorectal cancer (CRC) is one of the commonest cancers worldwide, and the mechanism of disease progression remains unknown. A large body of evidence indicates that genetic mutations, epigenetic changes, diet, and lifestyle are key risk factors for CRC initiation and progression. It is widely accepted that chronic inflammation plays an important role in cancer. Interleukin-17 (IL-17), produced by a T cell subset named "Th17", can promote cancer-elicited inflammation and prevent cancer cells from immune surveillance. Mounting evidence indicates that IL-17 is overexpressed in different cancer, including gastric cancer, cervical carcinoma, esophageal cancer, non-small-cell lung carcinoma, hepatocellular carcinoma, ovarian cancer, melanoma, lymphoma, breast cancer and prostate cancer, as well as CRC. IL-17 has been linked to intestinal inflammation and CRC development. Despite controversy, IL-17 is generally considered to be a promoter in CRC initiation and progression. In this review, we devote to summarize the current progress regarding the role of IL-17 in tumor initiation and progression, as well as the prognostic value in CRC.
- Publication
Progress in Modern Biomedicine, 2016, Vol 16, Issue 19, p3776
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2016.19.046